guest ::
| Home > Publications database > Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19. > print |
| Home > Publications database > Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19. > print |
| 001 | 168559 | ||
| 005 | 20240229133611.0 | ||
| 024 | 7 | _ | |a 10.1161/ATVBAHA.120.315698 |2 doi |
| 024 | 7 | _ | |a pmid:33910372 |2 pmid |
| 024 | 7 | _ | |a 0276-5047 |2 ISSN |
| 024 | 7 | _ | |a 1049-8834 |2 ISSN |
| 024 | 7 | _ | |a 1079-5642 |2 ISSN |
| 024 | 7 | _ | |a 1524-4636 |2 ISSN |
| 024 | 7 | _ | |a 2330-9180 |2 ISSN |
| 024 | 7 | _ | |a 2330-9199 |2 ISSN |
| 024 | 7 | _ | |a altmetric:104942783 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-00976 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Langnau, Carolin |b 0 |
| 245 | _ | _ | |a Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19. |
| 260 | _ | _ | |a Stanford, Calif. |c 2021 |b HighWire |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1625060211_24032 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Jun;41(6):2080-2096 |
| 520 | _ | _ | |a Patients with coronary artery disease (CAD) are at increased risk for cardiac death and respiratory failure following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Platelets are crucially involved in pathogenesis of CAD and might also contribute to pathophysiology of SARS-CoV-2 infection. Approach and Results: We enrolled a cohort of 122 participants from February 2020 to July 2020 including 55 patients with preexisting CAD and acute SARS-CoV-2 infection (CAD-SARS-CoV-2positive), 28 patients with CAD and without SARS-CoV-2 (CAD-SARS-CoV-2negative), and 39 healthy controls. Clinical and cardiac examination of the CAD-SARS-CoV-2positive group included blood sampling, echocardiography, and electrocardiography within 24 hours after hospital admission. Phenotyping of platelets was performed by flow cytometry; plasma levels of chemokines were analyzed by ELISA. Respiratory failure of patients was stratified by the Horovitz index as moderately/severely impaired when Horovitz index <200 mm Hg. The clinical end point was defined as Horovitz index <200 mm Hg with subsequent mechanical ventilation within a follow-up of 60 days. CAD-SARS-CoV-2positive patients display a significant enhanced platelet activation and hyper-inflammation early at time of hospital admission. Circulating platelet/leukocyte co-aggregates correlate with plasma levels of cytokines/chemokines like IL (interleukin)-6, CCL2, and CXCL10 as well as activation of platelets is associated with CCL5 and elevation of pulmonary artery pressure. Furthermore, furin is stored and released from activated platelets. High furin plasma levels are associated with poor clinical prognosis in CAD-SARS-CoV-2positive patients.Patients with CAD and SARS-CoV-2 infection exhibit elevated systemic platelet activation and enhanced plasma levels of the subtilisin-like proprotein convertase furin, which may contribute to an unfavorable clinical prognosis. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |x 0 |f POF IV |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a coronary artery disease |2 Other |
| 650 | _ | 7 | |a cytokines |2 Other |
| 650 | _ | 7 | |a flow cytometry |2 Other |
| 650 | _ | 7 | |a furin |2 Other |
| 650 | _ | 7 | |a pulmonary artery |2 Other |
| 700 | 1 | _ | |a Rohlfing, Anne-Katrin |b 1 |
| 700 | 1 | _ | |a Gekeler, Sarah |b 2 |
| 700 | 1 | _ | |a Günter, Manina |0 P:(DE-He78)b676990c2f64e3295740d42e356fb053 |b 3 |u dkfz |
| 700 | 1 | _ | |a Pöschel, Simone |b 4 |
| 700 | 1 | _ | |a Petersen-Uribe, Álvaro |b 5 |
| 700 | 1 | _ | |a Jaeger, Philippa |b 6 |
| 700 | 1 | _ | |a Avdiu, Alban |b 7 |
| 700 | 1 | _ | |a Harm, Tobias |b 8 |
| 700 | 1 | _ | |a Kreisselmeier, Klaus-Peter |b 9 |
| 700 | 1 | _ | |a Castor, Tatsiana |b 10 |
| 700 | 1 | _ | |a Bakchoul, Tamam |b 11 |
| 700 | 1 | _ | |a Rath, Dominik |b 12 |
| 700 | 1 | _ | |a Gawaz, Meinrad Paul |b 13 |
| 700 | 1 | _ | |a Autenrieth, Stella E |0 P:(DE-He78)d3dbba28fe1239effd15962787cbc363 |b 14 |u dkfz |
| 700 | 1 | _ | |a Mueller, Karin Anne Lydia |b 15 |
| 773 | _ | _ | |a 10.1161/ATVBAHA.120.315698 |g p. ATVBAHA.120.315698ATVBAHA.120.315698 |0 PERI:(DE-600)1494427-3 |n 6 |p 2080-2096 |t Arteriosclerosis, thrombosis, and vascular biology |v 41 |y 2021 |x 1524-4636 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:168559 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)b676990c2f64e3295740d42e356fb053 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 14 |6 P:(DE-He78)d3dbba28fe1239effd15962787cbc363 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-316 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Infections and cancer |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Allianz-Lizenz |0 StatID:(DE-HGF)0410 |2 StatID |d 2021-02-03 |w ger |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-02-03 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-03 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-03 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ARTERIOSCL THROM VAS : 2019 |d 2021-02-03 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ARTERIOSCL THROM VAS : 2019 |d 2021-02-03 |
| 920 | 1 | _ | |0 I:(DE-He78)F171-20160331 |k F171 |l Dentritische Zellen bei Infektionen und Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F171-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|